Newsfeeds - Spark Newswire

1 minute read

Biotech
FDA
General
Health Care
News
Small Cap

Oric Pharma’s ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors

Today, 12:31 PM

Oric Pharmaceuticals Inc (NASDAQ:ORIC) has announced initial data from an ongoing Phase 1b study evaluating ORIC-101 in combination with nab-paclitaxel, in…

ORIC

1 minute read

News

ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented At ASCO From Phase 1b Trial Of ORIC-101 In Combination With Nab-Paclitaxel

By Benzinga Newsdesk

Today, 12:31 PM

Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuations ORIC-101 plasma

ORIC

Latest news

Oric Pharma’s ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors

ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented At ASCO From Phase 1b Trial Of ORIC-101 In Combination With Nab-Paclitaxel